RxDoctor Payments DataLook up a doctor →

Ashish Shah, DO

Hematology & Oncology · Springfield, NJNPI 1285820274

Payments from drug & device makers

$394,099in general payments, 2019–2025

Across 780 payments — averaging $505.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262K
  • Jazz Pharmaceuticals Inc.$83K
  • E.r. Squibb & Sons, L.L.C.$23K
  • Pfizer$12K
  • Bristol Myers Squibb$3K
  • CTI Biopharma Corp.$3K
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie274$261,785
Jazz Pharmaceuticals Inc.76$82,577
E.r. Squibb & Sons, L.L.C.29$22,709
Pfizer45$12,305
Bristol Myers Squibb35$3,346
CTI Biopharma Corp.4$2,759
Johnson & Johnson(2 entities)34$1,825
Incyte Corporation14$1,512
Novartis34$559
Seagen Inc.16$428
Merck18$373
AstraZeneca(2 entities)14$283
Genentech USA, Inc.15$264
Amgen12$211
Sanofi6$190
Beigene USA, Inc.4$183
Gilead(2 entities)12$183
GSK10$180
Astellas Pharma US Inc10$149
Takeda Pharmaceuticals U.S.A., Inc.7$123
Celltrion USA Inc.1$114
Exelixis Inc.3$109
Foundation Medicine, Inc.3$103
Daiichi Sankyo Inc.6$102
Lilly USA, LLC6$92
Taiho Oncology, Inc.5$91
Philips North America LLC2$90
Bayer5$85
Regeneron Healthcare Solutions, Inc.5$83
Eisai Inc.5$72
Array Biopharma Inc4$71
Stemline Therapeutics Inc.4$71
Rigel Pharmaceuticals, Inc.5$66
Pharmacosmos Therapeutics Inc.3$61
Genmab U.S., Inc.3$60
Morphosys, US Inc.3$47
Mirati Therapeutics, Inc.2$44
ADC Therapeutics America, Inc.2$44
Pharmaessentia USA Corporation3$43
Adaptive Biotechnologies Corporation2$43
Servier Pharmaceuticals LLC3$43
Beone Medicines USA, Inc.2$40
Azurity Pharmaceuticals, Inc.2$39
Secura Bio, Inc.2$36
EMD Serono, Inc.2$35
Sobi, Inc2$34
Deciphera Pharmaceuticals Inc.2$32
AVEO Pharmaceuticals, Inc.1$30
Epizyme, Inc.2$30
Acceleron Pharma, Inc.2$29
Pharmacyclics LLC, An Abbvie Company2$27
Menarini Silicon Biosystems, Inc.1$24
Dendreon Pharmaceuticals LLC1$22
Springworks Therapeutics, Inc.1$21
Sirtex Medical Inc1$20
Agios Pharmaceuticals, Inc.1$20
Myriad Genetic Laboratories, Inc.1$19
Blueprint Medicines Corporation1$18
Legend Biotech USA Inc.1$18
Ipsen Biopharmaceuticals, Inc1$17

How this compares

$394,099 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$256,678
Medicare patients
748
Services billed
2,463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Springfield

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →